Generic Therapy after Exposure to Biological Warfare Agents: Validation of an in Vitro Dendritic Cell Culture System

Abstract

The threat of the use of biological weapons, including bacteria, has increased. Bacterial resistance to antibiotics increasingly becomes a problem. Vaccination of military personnel against biothreat agents may be an option, however there is a broad range of biothreat agents, which may become even broader as a result of genetic engineering. Moreover, vaccination against multiple agents may cause undesired effects. A more generic approach to prevent the effects of a broad spectrum of bacteria via immunomodulation seems more effective. To be able to study the development of immune responses against bio-threat bacteria to select potential broad-spectrum therapeutics, an in vitro culture system of dendritic cells was chosen, since this cell type plays a central role in the development of immune responses. A dendritic cell culture system was validated using model compounds of which the effects on dendritic cells are known (LPS, IFN-gamma, PGE2). The system was analyzed by measuring expression of surface markers on dendritic cells as well as cytokine production by dendritic cells and polarized T cells. All responses were in agreement with published literature in peer-reviewed journals.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2005
Accession Number
ADA453046

Entities

People

  • D. Van Der Kleif
  • M. Pohuijs

Tags

DTIC Thesaurus Topics

  • Adaptive Immunity
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Bacteria
  • Bacterial Infections
  • Biological Warfare
  • Biological Warfare Agents
  • Blood
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Culture Techniques
  • Immunomodulation
  • Leukocytes
  • Lymphocytes
  • Medical Personnel
  • Proteins

Fields of Study

  • Medicine

Readers

  • Critical Infrastructure Protection in CBRN and WMD Threats.
  • Immunology
  • Microbial Pathology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech